Search Results
Feb 05, 2026, 17:52 ET Resolutions Adopted by the Extraordinary Shareholders' Meeting of February 5th 2026
General Shareholders' AssemblyGermán Ávila, Minister of Finance and Public Credit, was appointed as Chair of the Assembly.iii. Appointment of the Elections and Vote Counting Committee of the General Shareholders' AssemblyThe Elections and Vote Counting Committee proposed
More news about: Ecopetrol S.A.
Feb 05, 2026, 17:00 ET Post Holdings Reports Results for the First Quarter of Fiscal Year 2026; Raises Fiscal Year 2026 Outlook
assets, (ii) it presents a measure of corporate performance exclusive of Post's capital structure and the method by which the assets were acquired and (iii) it is a financial indicator of a company's ability to service its debt, as Post is required to comply with certain covenants and limitations that are
More news about: Post Holdings, Inc.
Feb 05, 2026, 16:15 ET CNO Financial Group Reports Fourth Quarter and Full Year 2025 Results
net investment income less: (i) equity returns credited to policyholder account balances; (ii) the investment income allocated to our product lines; (iii) interest expense on notes payable, investment borrowings and financing arrangements; (iv) expenses related to the funding agreement-backed notes ("FABN")
More news about: CNO Financial Group
Feb 05, 2026, 16:06 ET Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2025
growth in the markets we serve, including the proteomics market; (ii) the volume, timing and mix of customer orders among our products and services; (iii) our ability to adjust our operating expenses to align with our revenue expectations; (iv) our ability to successfully integrate SomaLogic, Inc. and
More news about: Illumina, Inc.
Feb 05, 2026, 16:05 ET CleanSpark Delivers $181 Million in Q1 Revenue, Strengthens Balance Sheet, and Advances Multi-Gigawatt AI Infrastructure Platform
performance, and for which the accounting requires management judgment, and the resulting expenses could vary significantly in comparison to other companies; (iii) non-cash impairment losses related to long-lived assets (including goodwill); (iv) realized gains and losses on sales of equity securities, the amounts
More news about: CleanSpark, Inc.
Feb 05, 2026, 14:00 ET Ginkgo Bioworks' Autonomous Laboratory Driven by OpenAI's GPT-5 Achieves 40% Improvement Over State-of-the-Art Scientific Benchmark
Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo's business, (iii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, including
More news about: Ginkgo Bioworks
Feb 05, 2026, 13:54 ET COLDWELL BANKER COMMERCIAL AFFILIATES ANNOUNCES 2025 YEAR-END AWARD WINNERS
Janesville, WIAJ Thoma IIIColdwell Banker Commercial Devonshire Realty
More news about: Coldwell Banker Commercial Affiliates
Feb 05, 2026, 13:42 ET P&F Secures EU MDR CE Certification for TricValve® System
The MDR CE certification applies to the TricValve system as a Class III active implantable medical device for patients with symptomatic severe tricuspid regurgitation (TR) and caval reflux who are at high risk for open-heart
More news about: P+F Products and Features
Feb 05, 2026, 10:22 ET DeFi Technologies gibt bekannt, dass das Venture-Portfoliounternehmen Stablecorp die VersaBank als Verwahrstelle für den QCAD Digital Trust ausgewählt hat, wodurch Kanadas erste konforme CAD-Stablecoin vorangetrieben wird
CAD-gebundener ETPs und strukturierter Lösungen), (ii) Liquidität und Marktzugang (einschließlich institutioneller Ausführung und On-/Off-Ramps) und (iii) Sicherheit und Zukunftssicherheit bei zunehmender Akzeptanz.Informationen zu dem QCAD Digital Trust und zu StablecorpDer QCAD
More news about: DeFi Technologies Inc.
Feb 05, 2026, 09:13 ET Eisai y Henlius firman un acuerdo comercial para el anticuerpo anti-PD-1 serplulimab en Japón
el año fiscal 2026, basándose en los resultados del estudio puente y los datos de la fase III que respaldan las aprobaciones en China y Europa. Además, está en curso un ensayo clínico multinacional de fase III para el cáncer colorrectal metastásico sin IMS alta, con desarrollos planificados en otras
More news about: Henlius
Feb 05, 2026, 09:00 ET Class Action Filed Against SLM Corporation (SLM) - February 17, 2026 Deadline to Join - Contact The Gross Law Firm
loss mitigation and/or loan modification programs, as well as the overall stability of the Company's private education loan delinquency rates; and (iii) as a result, defendants' public statements made a materially false and misleading impression regarding SLM's business, operations, and prospects at
More news about: The Gross Law Firm
Feb 05, 2026, 09:00 ET Lost Money on Beyond Meat, Inc.(BYND)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm
material, non-cash impairment charge; (ii) the foregoing was likely to impair Beyond Meat's ability to timely file its periodic filings with the SEC; and (iii) as a result, defendants' public statements were materially false and misleading at all relevant times.DEADLINE: March 24, 2026 Shareholders
More news about: The Gross Law Firm
Feb 05, 2026, 09:00 ET The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 13, 2026 in CoreWeave, Inc. Lawsuit - CRWV
that CoreWeave's reliance on a single third-party data center supplier presented for CoreWeave's ability to meet customer demand for its services; (iii) the foregoing was reasonably likely to have a material negative impact on the Company's revenue; (iv) as a result, the Company's public statements were
More news about: The Gross Law Firm
Feb 05, 2026, 07:30 ET Construction Partners, Inc. Announces Fiscal 2026 First Quarter Results
throughout the Sunbelt, today reported financial and operating results for the fiscal quarter ended December 31, 2025. Fred J. (Jule) Smith, III, the Company's President and Chief Executive Officer, said, "We are pleased to report a strong start to fiscal 2026, driven by outstanding operational
More news about: Construction Partners, Inc.
Feb 05, 2026, 07:27 ET Natural Grocers® Celebrates Iowa Day with a Special Gift and Savings Feb. 8-10, 2026
requirement in one transaction.[iii]Sign up by 2/5/26 to receive this coupon via
More news about: Natural Grocers by Vitamin Cottage, Inc.
Feb 05, 2026, 07:20 ET INVESTOR ALERT: Ultragenyx Pharmaceutical Inc. (RARE) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces
Ultragenyx' Phase III Orbit study would fail to achieve a statistically significant reduction in annualized fracture rate ("AFR"), such that the second interim analysis could be performed and presented to the investing public; and (ii) in truth, Ultragenyx' optimism in the Phase III Orbit study's results
More news about: Robbins Geller Rudman & Dowd LLP
Feb 05, 2026, 07:00 ET WEC Energy Group posts 2025 results
(2,781.1)Acquisition of Hardin Solar Energy III LLC, net of cash acquired of $0.2
More news about: WEC Energy Group
Feb 05, 2026, 06:56 ET Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan
ES-SCLC and plans to submit a regulatory application in fiscal year 2026 based on the bridging study results and Phase III data supporting approvals in China and Europe. In addition, a Phase III multinational clinical trial for non-MSI-High metastatic colorectal cancer is ongoing, with further development in
More news about: Henlius
Feb 05, 2026, 06:44 ET Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan
submit an application for fiscal year 2026 based on the results of this trial as well as the Phase III clinical trial data that supported approvals for this indication in China and Europe. Furthermore, a Phase III multi-national clinical trial for non-high-frequency microsatellite instability (non-MSI-High) metastatic
More news about: Henlius
Feb 05, 2026, 06:00 ET PhotonPharma Inc. Announces Recruitment for Phase 1 Clinical Trial of Innocell™ Autologous Cellular Immunotherapy for Recurrent Epithelial Ovarian Cancer
new cases diagnosed annually in the United States and approximately 13,000 deaths per year. Approximately 70-80% of patients are diagnosed at Stage III or IV, and the five-year survival rate remains approximately 50%. Despite advances in surgical techniques and chemotherapy regimens, recurrence rates
More news about: PhotonPharma Inc.
Feb 05, 2026, 06:00 ET The Cigna Group Reports Strong Fourth Quarter and Full Year 2025 Results, Establishes 2026 Outlook and Increases Dividend
services agreement issued by Cigna Healthcare; (ii) have access to Cigna Healthcare's provider network for covered services under their medical plan; or (iii) have medical claims that are administered by Cigna Healthcare.Total customer relationships and total medical customers as of December
More news about: The Cigna Group
Feb 05, 2026, 04:08 ET Dingdong Announces Entry into Definitive Agreement to Sell its China Business to Meituan
fee if it fails to satisfy certain material controllable conditions, or fails to cooperate in regulatory filings; and (iii) the Buyer shall pay a US$75 million termination fee if the Transaction fails and the required anti-monopoly approval or certain other regulatory clearance
More news about: Dingdong (Cayman) Limited
Feb 05, 2026, 00:00 ET Galaxy Brain Scientific's Technology Enables Landmark Parkinson's Study Published in Nature, Redefining Disease Mechanism
accuracy.Galaxy Brain Scientific is already moving to bring these insights to the clinical frontline, having begun a pivotal registration trial for Class III devices dedicated to treating PD. Beyond Parkinson's, the company is also pioneering the application of this technology to treat other complex brain
More news about: Galaxy Brain Scientific Inc.
Feb 04, 2026, 20:01 ET Unlikely Collaborators Hosts Spark Salon with Futures Designer Nick Foster on Rethinking How We Imagine the Future
artists, and collaborators for conversations that challenge perspectives and deepen connections. Past Spark Salon speakers have included illusionist Harris III, psychologist Scott Barry Kaufman, PhD, nutrition therapist Kim Shapira, MS, RD, mythologist John Bucher, Harvard Business School professor and author
More news about: Unlikely Collaborators
Feb 04, 2026, 17:31 ET Oncolytic Virus Clinical Trial Landscape Gains Momentum: 100+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
herpesvirus engineered to preferentially infect and destroy cancer cells, releasing GM-CSF to trigger a broader anti-tumor immune response.In the Phase III OPTiM trial, IMLYGIC produced durable responses in about 16% of patients, compared with 2% with GM-CSF alone, and overall responses in roughly 26%. Patients
More news about: DelveInsight Business Research, LLP